{"altmetric_id":21008533,"counts":{"readers":{"mendeley":8,"citeulike":0,"connotea":0},"total":{"posts_count":13},"twitter":{"unique_users_count":13,"unique_users":["luddyka","eduardo_moros","ChrisHeery","aideenryan1","JamesRMansfield","NKcellBiology","INmuneBio","FrontImmunol","DrRaulCordoba","Inmunologia_UMU","vieramb","Gorksch","InmunoMedUMU"],"posts_count":13}},"selected_quotes":["Inmunoterapia para cancer y y virus usando c\u00e9lulas NK","NK Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular Therapies #ImmunoOnc"],"citation":{"abstract":"Immunotherapies based on natural killer (NK) cells are among the most promising therapies under development for the treatment of so far incurable forms of leukemia and other types of cancer. The importance of NK cells for the control of viral infections and cancer is supported among others by the findings that viruses and tumors use a multitude of mechanisms to subvert and evade the NK cell system. Infections and malignant diseases can further lead to the shaping of NK cell populations with altered reactivity. Counter measures of potential therapeutic impact include the blocking of inhibitory interactions between NK cell receptors and their cellular ligands, the enhancement of activating receptor signals, and the infusion of large numbers of ex vivo generated and selected NK cells. Moreover, the specific cross-linking of NK cells to their target cells using chimeric antigen receptors or therapeutic bi-\/trispecific antibody reagents is a promising approach. In this context, NK cells stand out by their positive effects and safety demonstrated in most clinical trials so far. Based in part on results of the recent EC-sponsored project \"NATURIMMUN\" and considering additional published work in the field, we discuss below new developments and future directions that have the potential to further advance and establish NK cell-based therapies at the clinics on a broader scale.","altmetric_jid":"4f6fa90c3cf058f61000cb02","authors":["Hofer, Erhard","Koehl, Ulrike"],"doi":"10.3389\/fimmu.2017.00745","first_seen_on":"2017-06-12T21:20:31+00:00","funders":["niehs"],"handles":[],"issns":["1664-3224"],"journal":"Frontiers in immunology","last_mentioned_on":1502293346,"links":["http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00745\/abstract","https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28747910?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter","http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00745\/full","http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00745\/full?utm_source=S-TWT&utm_medium=SNET&utm_campaign=ECO_FIMMU_XXXXXXXX_auto-dlvrit","https:\/\/doi.org\/10.3389\/fimmu.2017.00745"],"pmcid":"PMC5506076","pmid":"28747910","pubdate":"2017-01-01T00:00:00+00:00","publisher":"Frontiers","title":"Natural killer cell-based cancer immunotherapies: from immune evasion to promising targeted cellular therapies","type":"article","volume":"8","mendeley_url":"http:\/\/www.mendeley.com\/research\/natural-killer-cellbased-cancer-immunotherapies-immune-evasion-promising-targeted-cellular-therapies"},"altmetric_score":{"score":7.2,"score_history":{"1y":7.2,"6m":7.2,"3m":7.2,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7.2},"context_for_score":{"all":{"total_number_of_other_articles":8348788,"mean":7.0413328717018,"rank":1205055,"this_scored_higher_than_pct":85,"this_scored_higher_than":7140993,"rank_type":"exact","sample_size":8348788,"percentile":85},"similar_age_3m":{"total_number_of_other_articles":241578,"mean":12.603036009223,"rank":49765,"this_scored_higher_than_pct":79,"this_scored_higher_than":191666,"rank_type":"exact","sample_size":241578,"percentile":79},"this_journal":{"total_number_of_other_articles":3654,"mean":3.075001368738,"rank":287,"this_scored_higher_than_pct":92,"this_scored_higher_than":3363,"rank_type":"exact","sample_size":3654,"percentile":92},"similar_age_this_journal_3m":{"total_number_of_other_articles":220,"mean":3.752401826484,"rank":22,"this_scored_higher_than_pct":90,"this_scored_higher_than":198,"rank_type":"exact","sample_size":220,"percentile":90}}},"demographics":{"poster_types":{"member_of_the_public":8,"researcher":3,"practitioner":2},"users":{"twitter":{"cohorts":{"Members of the public":8,"Scientists":3,"Practitioners (doctors, other healthcare professionals)":2}},"mendeley":{"by_status":{"Unspecified":1,"Researcher":4,"Student  > Ph. D. Student":2,"Student  > Master":1},"by_discipline":{"Medicine and Dentistry":1,"Immunology and Microbiology":1,"Agricultural and Biological Sciences":3,"Biochemistry, Genetics and Molecular Biology":1,"Unspecified":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"IE":1,"US":2,"CH":1,"ES":2,"MX":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/luddyka\/statuses\/874375798513442816","license":"gnip","citation_ids":[21008533],"posted_on":"2017-06-12T21:20:10+00:00","author":{"name":"Kim Luddy","image":"https:\/\/pbs.twimg.com\/profile_images\/751759990675955712\/VwALtRfv_normal.jpg","description":"I obsess over immunology & cancer. Supporter of open access. Wildly annoyed by unquestioned dogma. Enjoying being a mom working in STEM.\nLogo by @simonfayauthor","id_on_source":"luddyka","tweeter_id":"439359840","geo":{"lt":53.33306,"ln":-6.24889,"country":"IE"},"followers":964},"tweet_id":"874375798513442816"},{"url":"http:\/\/twitter.com\/eduardo_moros\/statuses\/874380510897860608","license":"gnip","rt":["luddyka"],"citation_ids":[21008533],"posted_on":"2017-06-12T21:38:53+00:00","author":{"name":"Eduardo Moros","url":"http:\/\/orcid.org\/0000-0003-1964-2460","image":"https:\/\/pbs.twimg.com\/profile_images\/690592111503212544\/R7nx_erN_normal.jpg","description":"Twitting Cancer, Medical Physics, Radiomics, MR-Guided Adaptive Radiotherapy, Mathematical RadioOncology, RT & Immunology, Florida & Venezuela.","id_on_source":"eduardo_moros","tweeter_id":"1502579419","geo":{"lt":28.75054,"ln":-82.5001,"country":"US"},"followers":623},"tweet_id":"874380510897860608"},{"url":"http:\/\/twitter.com\/ChrisHeery\/statuses\/874390540422438912","license":"gnip","rt":["luddyka"],"citation_ids":[21008533],"posted_on":"2017-06-12T22:18:44+00:00","author":{"name":"Christopher Heery","image":"http:\/\/pbs.twimg.com\/profile_images\/378800000728197658\/3c574b727c2153006d1cdb989299948e_normal.jpeg","description":"Medical Immuno-Oncologist, Translational Clinical Trials. In pursuit of cure. Tweets are my opinions and do not represent NCI.","id_on_source":"ChrisHeery","tweeter_id":"2189156778","followers":611},"tweet_id":"874390540422438912"},{"url":"http:\/\/twitter.com\/aideenryan1\/statuses\/874708152524165120","license":"gnip","rt":["luddyka"],"citation_ids":[21008533],"posted_on":"2017-06-13T19:20:49+00:00","author":{"name":"Aideen Ryan","image":"https:\/\/pbs.twimg.com\/profile_images\/805367783999442944\/boS0ExI4_normal.jpg","description":"Immunology enthusiast. Foundation Research Lecturer and Research group lead in Tumour immunology at NUIG. All opinions are my own.","id_on_source":"aideenryan1","tweeter_id":"253104801","geo":{"lt":null,"ln":null},"followers":174},"tweet_id":"874708152524165120"},{"url":"http:\/\/twitter.com\/JamesRMansfield\/statuses\/875505031872741376","license":"gnip","rt":["luddyka"],"citation_ids":[21008533],"posted_on":"2017-06-16T00:07:20+00:00","author":{"name":"Jim Mansfield","url":"http:\/\/jmansfield.com","image":"https:\/\/pbs.twimg.com\/profile_images\/2641187420\/4dc8581e6b89ef3119a63d5ceaee54f9_normal.jpeg","description":"Scientist, sports fan and amateur musician. Working @AndorTechnology as their global head of OEM business development. Tweets are my own!","id_on_source":"JamesRMansfield","tweeter_id":"460670530","geo":{"lt":null,"ln":null},"followers":407},"tweet_id":"875505031872741376"},{"url":"http:\/\/twitter.com\/NKcellBiology\/statuses\/890911107073810432","license":"gnip","citation_ids":[21008533],"posted_on":"2017-07-28T12:25:34+00:00","author":{"name":"NK cell Biology","image":"https:\/\/pbs.twimg.com\/profile_images\/520597683086450689\/gybS02Uf_normal.jpeg","description":"Twitterbot of #NKcell papers in #PubMed. Keeping you up to date with the latest in natural killer cell biology and immunology.","id_on_source":"NKcellBiology","tweeter_id":"2849742042","geo":{"lt":null,"ln":null},"followers":71},"tweet_id":"890911107073810432"},{"url":"http:\/\/twitter.com\/INmuneBio\/statuses\/892220643537690624","license":"gnip","citation_ids":[21008533],"posted_on":"2017-08-01T03:09:12+00:00","author":{"name":"INmuneBio","url":"http:\/\/www.inmunebio.com","image":"https:\/\/pbs.twimg.com\/profile_images\/905170999813001216\/m1RyyQxB_normal.jpg","description":"INmune Bio, Inc. is developing therapies that harness the patient's immune system to treat cancer.","id_on_source":"INmuneBio","tweeter_id":"783331147812048896","geo":{"lt":32.71533,"ln":-117.15726,"country":"US"},"followers":69},"tweet_id":"892220643537690624"},{"url":"http:\/\/twitter.com\/FrontImmunol\/statuses\/894579682317709313","license":"gnip","citation_ids":[21008533],"posted_on":"2017-08-07T15:23:11+00:00","author":{"name":"Frontiers Immunology","url":"http:\/\/frontiersin.org\/Immunology","image":"https:\/\/pbs.twimg.com\/profile_images\/533290695813918721\/D6Z7R9Qu_normal.jpeg","description":"The official Twitter Feed for all the latest open-access peer-reviewed articles appearing in Frontiers in Immunology.  Impact Factor: 6.429.","id_on_source":"FrontImmunol","tweeter_id":"397381576","geo":{"lt":46.516,"ln":6.63282,"country":"CH"},"followers":3897},"tweet_id":"894579682317709313"},{"url":"http:\/\/twitter.com\/DrRaulCordoba\/statuses\/894592565277863937","license":"gnip","citation_ids":[21008533],"posted_on":"2017-08-07T16:14:22+00:00","author":{"name":"Raul Cordoba","url":"http:\/\/www.fjd.es","image":"https:\/\/pbs.twimg.com\/profile_images\/817087500850229248\/LRpwr7_9_normal.jpg","description":"\ud83c\uddea\ud83c\uddf8Mi Vocaci\u00f3n? La Medicina. Mi Pasi\u00f3n? La Hematolog\u00eda. Mi especialidad? Los Linfomas \ud83c\uddfa\ud83c\uddf8Doctor. Hematologist. Interest in #lymphoma #CLL #gerionc #ImmunoOnc","id_on_source":"DrRaulCordoba","tweeter_id":"1697360292","geo":{"lt":40.42526,"ln":-3.69063,"country":"ES"},"followers":2028},"tweet_id":"894592565277863937"},{"url":"http:\/\/twitter.com\/Inmunologia_UMU\/statuses\/894594892848037888","license":"gnip","rt":["FrontImmunol"],"citation_ids":[21008533],"posted_on":"2017-08-07T16:23:37+00:00","author":{"name":"Inmunolog\u00eda UMU","image":"https:\/\/pbs.twimg.com\/profile_images\/778560056757477376\/PZ2LFuru_normal.jpg","description":"Grupo de Investigaci\u00f3n e Innovaci\u00f3n Docente de Inmunolog\u00eda de la Universidad de Murcia","id_on_source":"Inmunologia_UMU","tweeter_id":"778541586745593856","geo":{"lt":38,"ln":-1.5,"country":"ES"},"followers":149},"tweet_id":"894594892848037888"},{"url":"http:\/\/twitter.com\/vieramb\/statuses\/894754561360932867","license":"gnip","citation_ids":[21008533],"posted_on":"2017-08-08T02:58:05+00:00","author":{"name":"Javier Ambrosio","url":"http:\/\/www.facmed.unam.mx\/marco\/index.php?dir_ver=87","image":"https:\/\/pbs.twimg.com\/profile_images\/425815350739869696\/XhI4jsM__normal.jpeg","description":"Dr en Biomedicina (UNAM), Prof Tit  (UNAM). Investigador Nacional (SNI).","id_on_source":"vieramb","tweeter_id":"58006038","geo":{"lt":19.35993,"ln":-99.29388,"country":"MX"},"followers":155},"tweet_id":"894754561360932867"},{"url":"http:\/\/twitter.com\/Gorksch\/statuses\/894851981445038080","license":"gnip","rt":["FrontImmunol"],"citation_ids":[21008533],"posted_on":"2017-08-08T09:25:12+00:00","author":{"name":"Gorka","image":"https:\/\/pbs.twimg.com\/profile_images\/881111613071400960\/upL2TxyS_normal.jpg","description":"Al final todo saldr\u00e1 bien y si no sale bien es que a\u00fan no es el final","id_on_source":"Gorksch","tweeter_id":"3206703639","geo":{"lt":null,"ln":null},"followers":119},"tweet_id":"894851981445038080"},{"url":"http:\/\/twitter.com\/InmunoMedUMU\/statuses\/895309303472631808","license":"gnip","rt":["FrontImmunol"],"citation_ids":[21008533],"posted_on":"2017-08-09T15:42:26+00:00","author":{"name":"PedroAparicio","image":"https:\/\/pbs.twimg.com\/profile_images\/786132948357709824\/Byu_MNYo_normal.jpg","description":"Profesor inmunolog\u00eda Universidad de Murcia.Facebook pedro.aparicio.100","id_on_source":"InmunoMedUMU","tweeter_id":"786118672343457793","geo":{"lt":null,"ln":null},"followers":136},"tweet_id":"895309303472631808"}]}}